Collectionner le produit
Détails du produit
Synonyms
ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1
Source
PE-Labeled Human Her2, His Tag (HE2-HP2E3) is produced via conjugation of PE to Human Her2, His Tag under optimal conditions. Human Her2, His Tag is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).
Predicted N-terminus: Thr 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 73.0 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Evaluation of anti-HER2 CAR expression by flow cytometry. Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-Flow Cytometry
5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Her2, His Tag (Cat. No. HE2-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
I***l2024-09-27
J'aimeWe used the PE-labeled recombinant ErbB2 protein to detect our HER2-specific CAR constructs. The protein performed exceptionally well, providing a strong and consistent fluorescence signal when analyzing stained samples via flow cytometry. The staining was highly specific, since we detected no background-signal on parental cell-lines lacking the CAR. This is in contrast to staining of CAR expressing cells using ErbB2-Fc in combination with secondary antibodies which often results in higher non-specific signals and is more time consuming. Hence, ErbB2-PE is a valuable tool to detect ErbB2-specific CAR expression via Flow cytometry.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Receptor protein-tyrosine kinase erbB-2
- Catégorie：
- Nombre de médicaments répertoriés：
47 Détails
- Nombre de médicaments cliniques：
238 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
